#United States #Veeva Systems #Pleasanton #Vault CRM #Veeva Falcon

Veeva Systems Reports Impressive Fiscal 2027 Second Quarter Results

Veeva Systems Inc. (NYSE: VEEV), a renowned leader in providing industry cloud solutions specifically for the life sciences sector, recently shared its remarkable financial results for the second quarter of fiscal 2027, which concluded on July 31, 2026. The company has witnessed a significant rise in both total and subscription revenues, illustrating the growing demand and successful adoption of its innovative technologies across the industry.

Financial Highlights

The total revenues for this quarter reached an impressive $928.0 million, marking an 18% increase year-over-year from $789.1 million recorded in the same period last year. Meanwhile, subscription revenues rose to $766.8 million, which is a 16% increase from last year's $659.2 million. The growth highlights Veeva’s solid position within the competitive life sciences landscape.

In terms of operating income, Veeva reported $275.0 million, up 40% from $195.9 million last year, and the company’s non-GAAP operating income reached $415.9 million, reflecting an 18% increase over the previous year. Net income climbed to $273.4 million, up from $200.3 million year-over-year, representing a healthy 37% growth. When calculating non-GAAP net income, the increase was 16%, bringing it to $387.4 million.

The fully diluted net income per share for this quarter is $1.66, up from $1.19 last year, while the non-GAAP fully diluted net income per share saw an increase to $2.35 from $1.99.

Management Insights

Veeva’s CEO, Peter Gassner, emphasized the transformative impact that AI is having on the life sciences sector, indicating that it is ushering in a new era of efficiency and innovation. He elaborated that the success of the Vault CRM platform was particularly notable this quarter, achieving its best performance to date. Gassner remarked, “By integrating deep industry applications alongside comprehensive data and consulting services, we are actively pushing the boundaries of what is possible in clinical and commercial settings, ultimately benefiting patient outcomes.”

CFO Brian Van Wagener added that all metrics exceeded expectations, expressing confidence in the company's trajectory and reaffirming their positive outlook for the remainder of the fiscal year.

Recent Highlights

Key developments during this quarter included:

• - Growth in Vault CRM Leadership: The Vault CRM platform has seen substantial adoption, now with over 180 customers live, including commitments from 12 of the world's top 20 biopharmaceutical companies. Two such companies entered agreements for Vault CRM this quarter, validating its position as a leading CRM solution.
• - Advancements in AI: Veeva Falcon, the company's innovative agentic platform, is rapidly progressing, with five early adopters in the queue for initial implementations this year. Additionally, the recent acquisition of Copli has bolstered Veeva's capabilities in automating content review processes through the new Veeva Falcon MLR.
• - Enhanced Relationships in Research and Development: Both the Development Cloud and Quality Cloud are seeing broad adoption, with a significant enterprise biopharma selecting Veeva’s EDC as part of an extensive technology framework, strengthening customer bonds and illustrating Veeva's ability to meet complex industry needs.

Financial Outlook

For the upcoming fiscal third quarter, Veeva projects total revenues in the range of $932 to $935 million and non-GAAP operating income expected between $417 and $420 million. Additionally, they forecast non-GAAP fully diluted net income per share to range between $2.33 and $2.34.

For the overall fiscal year ending January 31, 2027, Veeva is optimistic, projecting total revenues between $3,682 and $3,687 million and non-GAAP operating income around $1,640 million.

The conference call detailing these results will be hosted on August 26, 2026, at 2:00 PM PT, allowing investors and stakeholders to delve deeper into the company's strategies and performance metrics.

Conclusion

Veeva Systems continues to navigate well within the rapidly evolving life sciences sector, marked by solid revenue growth and strategic advancements in technology. With a clear focus on innovation and customer success, Veeva is well-positioned to enhance operational efficiencies and impact patient outcomes positively in the forthcoming quarters.